Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171700 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2 study, sponsored by pharmaand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT04171700 is a Phase 2 study that was terminated before completion, run by pharmaand. The registered enrollment target is 83 participants.
The verdict
NCT04171700, a Phase 2 study, was terminated before completion, sponsored by pharmaand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-01-16 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171700
The ClinicalTrials.gov registry entry for NCT04171700 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT04171700 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04171700 about?
NCT04171700 is a clinical study titled "A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes". A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
What is the current status of trial NCT04171700?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2020-01-16. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04171700?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT04171700?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.